Chapter 1. Preface

1.1 Report Description and Scope
1.2 Research Scope
1.3 Research Methodology
1.3.1 Market Research Type
1.3.2 Market Research Methodology

Chapter 2. Executive Summary

2.1 Global Microbiome Therapeutics Market, (2026 - 2035) (USD Billion)
2.2 Global Microbiome Therapeutics Market: Snapshot

Chapter 3. Global Microbiome Therapeutics Market - Industry Analysis

3.1 Microbiome Therapeutics Market: Market Dynamics
3.2 Market Drivers
3.2.1 The market is driven by the increasing global burden of chronic diseases linked to microbiome dysbiosis, rapid advancements in next-generation sequencing (NGS) and bioinformatics for identifying precision live biotherapeutics, and heightened investment in R&D fueled by the success of first-in-class FDA approvals.
3.3 Market Restraints
3.3.1 Expansion is hindered by stringent and evolving regulatory pathways for biologics, the high complexity and inter-individual variability of the human microbiome which complicates therapy standardization, and the significant capital requirements for specialized anaerobic manufacturing and cold-chain logistics.
3.4 Market Opportunities
3.4.1 Significant potential lies in the integration of AI-driven predictive modeling for personalized treatments, the expansion of therapeutic indications into oncology (checkpoint inhibitor response) and the gut-brain axis, and the rising demand for microbiome-based diagnostics as companion tools for clinical trials.
3.5 Market Challenges
3.5.1 Key hurdles include establishing definitive clinical causality in large-scale trials, overcoming intellectual property complexities regarding naturally occurring microbial strains, and managing the operational risks of donor-derived material sourcing for fecal microbiota transplants (FMT).
3.6 Porter’s Five Forces Analysis
3.7 Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Product Type
3.7.2 Market Attractiveness Analysis By Application
3.7.3 Market Attractiveness Analysis By End-User

Chapter 4. Global Microbiome Therapeutics Market- Competitive Landscape

4.1 Company Market Share Analysis
4.1.1 Global Microbiome Therapeutics Market: Company Market Share, 2025
4.2 Strategic Development
4.2.1 Acquisitions & mergers
4.2.2 New Product launches
4.2.3 Agreements, partnerships, collaborations, and joint ventures
4.2.4 Research and development and regional expansion
4.3 Price Trend Analysis

Chapter 5. Global Microbiome Therapeutics Market - Product Type Analysis

5.1 Global Microbiome Therapeutics Market Overview: Product Type
5.1.1 Global Microbiome Therapeutics Market share, By Product Type, 2025 and 2035
5.2 FMT
5.2.1 Global Microbiome Therapeutics Market by FMT, 2026 - 2035 (USD Billion)
5.3 LBPs
5.3.1 Global Microbiome Therapeutics Market by LBPs, 2026 - 2035 (USD Billion)
5.4 Probiotics
5.4.1 Global Microbiome Therapeutics Market by Probiotics, 2026 - 2035 (USD Billion)
5.5 Prebiotics
5.5.1 Global Microbiome Therapeutics Market by Prebiotics, 2026 - 2035 (USD Billion)
5.6 Synbiotics
5.6.1 Global Microbiome Therapeutics Market by Synbiotics, 2026 - 2035 (USD Billion)
5.7 Postbiotics
5.7.1 Global Microbiome Therapeutics Market by Postbiotics, 2026 - 2035 (USD Billion)
5.8 Diagnostic Tests
5.8.1 Global Microbiome Therapeutics Market by Diagnostic Tests, 2026 - 2035 (USD Billion)
5.9 Drugs
5.9.1 Global Microbiome Therapeutics Market by Drugs, 2026 - 2035 (USD Billion)
5.10 Supplements
5.10.1 Global Microbiome Therapeutics Market by Supplements, 2026 - 2035 (USD Billion)
5.11 Foods
5.11.1 Global Microbiome Therapeutics Market by Foods, 2026 - 2035 (USD Billion)

Chapter 6. Global Microbiome Therapeutics Market - Application Analysis

6.1 Global Microbiome Therapeutics Market Overview: Application
6.1.1 Global Microbiome Therapeutics Market Share, By Application, 2025 and 2035
6.2 Gastrointestinal Disorders
6.2.1 Global Microbiome Therapeutics Market by Gastrointestinal Disorders, 2026 - 2035 (USD Billion)
6.3 Metabolic Disorders
6.3.1 Global Microbiome Therapeutics Market by Metabolic Disorders, 2026 - 2035 (USD Billion)
6.4 Infectious Diseases
6.4.1 Global Microbiome Therapeutics Market by Infectious Diseases, 2026 - 2035 (USD Billion)
6.5 Immunological Disorders
6.5.1 Global Microbiome Therapeutics Market by Immunological Disorders, 2026 - 2035 (USD Billion)
6.6 Dermatological Disorders
6.6.1 Global Microbiome Therapeutics Market by Dermatological Disorders, 2026 - 2035 (USD Billion)
6.7 Neurological Disorders
6.7.1 Global Microbiome Therapeutics Market by Neurological Disorders, 2026 - 2035 (USD Billion)
6.8 Oncological Disorders
6.8.1 Global Microbiome Therapeutics Market by Oncological Disorders, 2026 - 2035 (USD Billion)
6.9 Respiratory Disorders
6.9.1 Global Microbiome Therapeutics Market by Respiratory Disorders, 2026 - 2035 (USD Billion)
6.10 Cardiovascular Disorders
6.10.1 Global Microbiome Therapeutics Market by Cardiovascular Disorders, 2026 - 2035 (USD Billion)
6.11 Hepatic Disorders
6.11.1 Global Microbiome Therapeutics Market by Hepatic Disorders, 2026 - 2035 (USD Billion)

Chapter 7. Global Microbiome Therapeutics Market - End-User Analysis

7.1 Global Microbiome Therapeutics Market Overview: End-User
7.1.1 Global Microbiome Therapeutics Market Share, By End-User, 2025 and 2035
7.2 Hospitals
7.2.1 Global Microbiome Therapeutics Market by Hospitals, 2026 - 2035 (USD Billion)
7.3 Clinics
7.3.1 Global Microbiome Therapeutics Market by Clinics, 2026 - 2035 (USD Billion)
7.4 Ambulatory Surgical Centers
7.4.1 Global Microbiome Therapeutics Market by Ambulatory Surgical Centers, 2026 - 2035 (USD Billion)
7.5 Homecare
7.5.1 Global Microbiome Therapeutics Market by Homecare, 2026 - 2035 (USD Billion)
7.6 Research Institutes
7.6.1 Global Microbiome Therapeutics Market by Research Institutes, 2026 - 2035 (USD Billion)
7.7 Pharmaceutical Companies
7.7.1 Global Microbiome Therapeutics Market by Pharmaceutical Companies, 2026 - 2035 (USD Billion)
7.8 Diagnostic Labs
7.8.1 Global Microbiome Therapeutics Market by Diagnostic Labs, 2026 - 2035 (USD Billion)
7.9 Academic Institutions
7.9.1 Global Microbiome Therapeutics Market by Academic Institutions, 2026 - 2035 (USD Billion)
7.10 Retail Pharmacies
7.10.1 Global Microbiome Therapeutics Market by Retail Pharmacies, 2026 - 2035 (USD Billion)
7.11 Online Pharmacies
7.11.1 Global Microbiome Therapeutics Market by Online Pharmacies, 2026 - 2035 (USD Billion)

Chapter 8. Microbiome Therapeutics Market - Regional Analysis

8.1 Global Microbiome Therapeutics Market Regional Overview
8.2 Global Microbiome Therapeutics Market Share, by Region, 2025 & 2035 (USD Billion)
8.3 North America
8.3.1 North America Microbiome Therapeutics Market, 2026 - 2035 (USD Billion)
8.3.1.1 North America Microbiome Therapeutics Market, by Country, 2026 - 2035 (USD Billion)
8.3.2 North America Microbiome Therapeutics Market, by Product Type, 2026 - 2035
8.3.2.1 North America Microbiome Therapeutics Market, by Product Type, 2026 - 2035 (USD Billion)
8.3.3 North America Microbiome Therapeutics Market, by Application, 2026 - 2035
8.3.3.1 North America Microbiome Therapeutics Market, by Application, 2026 - 2035 (USD Billion)
8.3.4 North America Microbiome Therapeutics Market, by End-User, 2026 - 2035
8.3.4.1 North America Microbiome Therapeutics Market, by End-User, 2026 - 2035 (USD Billion)
8.4 Europe
8.4.1 Europe Microbiome Therapeutics Market, 2026 - 2035 (USD Billion)
8.4.1.1 Europe Microbiome Therapeutics Market, by Country, 2026 - 2035 (USD Billion)
8.4.2 Europe Microbiome Therapeutics Market, by Product Type, 2026 - 2035
8.4.2.1 Europe Microbiome Therapeutics Market, by Product Type, 2026 - 2035 (USD Billion)
8.4.3 Europe Microbiome Therapeutics Market, by Application, 2026 - 2035
8.4.3.1 Europe Microbiome Therapeutics Market, by Application, 2026 - 2035 (USD Billion)
8.4.4 Europe Microbiome Therapeutics Market, by End-User, 2026 - 2035
8.4.4.1 Europe Microbiome Therapeutics Market, by End-User, 2026 - 2035 (USD Billion)
8.5 Asia Pacific
8.5.1 Asia Pacific Microbiome Therapeutics Market, 2026 - 2035 (USD Billion)
8.5.1.1 Asia Pacific Microbiome Therapeutics Market, by Country, 2026 - 2035 (USD Billion)
8.5.2 Asia Pacific Microbiome Therapeutics Market, by Product Type, 2026 - 2035
8.5.2.1 Asia Pacific Microbiome Therapeutics Market, by Product Type, 2026 - 2035 (USD Billion)
8.5.3 Asia Pacific Microbiome Therapeutics Market, by Application, 2026 - 2035
8.5.3.1 Asia Pacific Microbiome Therapeutics Market, by Application, 2026 - 2035 (USD Billion)
8.5.4 Asia Pacific Microbiome Therapeutics Market, by End-User, 2026 - 2035
8.5.4.1 Asia Pacific Microbiome Therapeutics Market, by End-User, 2026 - 2035 (USD Billion)
8.6 Latin America
8.6.1 Latin America Microbiome Therapeutics Market, 2026 - 2035 (USD Billion)
8.6.1.1 Latin America Microbiome Therapeutics Market, by Country, 2026 - 2035 (USD Billion)
8.6.2 Latin America Microbiome Therapeutics Market, by Product Type, 2026 - 2035
8.6.2.1 Latin America Microbiome Therapeutics Market, by Product Type, 2026 - 2035 (USD Billion)
8.6.3 Latin America Microbiome Therapeutics Market, by Application, 2026 - 2035
8.6.3.1 Latin America Microbiome Therapeutics Market, by Application, 2026 - 2035 (USD Billion)
8.6.4 Latin America Microbiome Therapeutics Market, by End-User, 2026 - 2035
8.6.4.1 Latin America Microbiome Therapeutics Market, by End-User, 2026 - 2035 (USD Billion)
8.7 The Middle-East and Africa
8.7.1 The Middle-East and Africa Microbiome Therapeutics Market, 2026 - 2035 (USD Billion)
8.7.1.1 The Middle-East and Africa Microbiome Therapeutics Market, by Country, 2026 - 2035 (USD Billion)
8.7.2 The Middle-East and Africa Microbiome Therapeutics Market, by Product Type, 2026 - 2035
8.7.2.1 The Middle-East and Africa Microbiome Therapeutics Market, by Product Type, 2026 - 2035 (USD Billion)
8.7.3 The Middle-East and Africa Microbiome Therapeutics Market, by Application, 2026 - 2035
8.7.3.1 The Middle-East and Africa Microbiome Therapeutics Market, by Application, 2026 - 2035 (USD Billion)
8.7.4 The Middle-East and Africa Microbiome Therapeutics Market, by End-User, 2026 - 2035
8.7.4.1 The Middle-East and Africa Microbiome Therapeutics Market, by End-User, 2026 - 2035 (USD Billion)

Chapter 9. Company Profiles

9.1 Seres Therapeutics
9.1.1 Overview
9.1.2 Financials
9.1.3 Product Portfolio
9.1.4 Business Strategy
9.1.5 Recent Developments
9.2 Ferring Pharmaceuticals
9.2.1 Overview
9.2.2 Financials
9.2.3 Product Portfolio
9.2.4 Business Strategy
9.2.5 Recent Developments
9.3 Vedanta Biosciences
9.3.1 Overview
9.3.2 Financials
9.3.3 Product Portfolio
9.3.4 Business Strategy
9.3.5 Recent Developments
9.4 Finch Therapeutics
9.4.1 Overview
9.4.2 Financials
9.4.3 Product Portfolio
9.4.4 Business Strategy
9.4.5 Recent Developments
9.5 Enterome
9.5.1 Overview
9.5.2 Financials
9.5.3 Product Portfolio
9.5.4 Business Strategy
9.5.5 Recent Developments

Frequently Asked Questions

Microbiome therapeutics are treatments that modulate the human microbiome to restore microbial balance and address diseases, including FMT, LBPs, and targeted drugs.

Key factors include rising chronic disease prevalence, biotechnology advancements, regulatory approvals, increased R&D investments, and expanding applications in personalized medicine.

The Microbiome Therapeutics market is projected to grow from approximately USD 0.8 billion in 2025 to USD 6.1 billion by 2035.

The Microbiome Therapeutics market is expected to register a CAGR of 20.4% during the forecast period from 2026 to 2035.

North America will contribute notably, holding around 42% of the market share due to advanced R&D and regulatory support.

Major players include Seres Therapeutics, Ferring Pharmaceuticals, Vedanta Biosciences, Finch Therapeutics, Enterome, and MaaT Pharma, driving growth through innovation and clinical advancements.

The report offers in-depth analysis of market size, trends, segmentation, regional dynamics, key players, and forecasts to aid strategic decision-making for stakeholders.

The value chain encompasses research and discovery (microbial identification), development (formulation and trials), manufacturing (culturing and encapsulation), distribution (supply and logistics), and end-use (administration and monitoring).

Trends are evolving toward personalized, AI-enhanced therapies with preferences shifting to non-invasive, natural microbiome modulators for holistic health management.

Regulatory factors include FDA and EMA classifications as biologics requiring rigorous trials, while environmental factors involve sustainable microbial sourcing to minimize ecological disruption and ensure ethical practices.